<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184064</url>
  </required_header>
  <id_info>
    <org_study_id>HVS-007</org_study_id>
    <nct_id>NCT03184064</nct_id>
  </id_info>
  <brief_title>Acute Effects of Blackcurrant and Citrus Polyphenol Extracts on Postprandial Glycaemia</brief_title>
  <acronym>Glu-FX</acronym>
  <official_title>Acute Effects of Blackcurrant and Citrus Polyphenol Extracts on Postprandial Glycaemia: The Glu-FX Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lucozade Ribena Suntory</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lucozade Ribena Suntory</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Large postprandial glucose responses are associated with increased risk of chronic diseases,&#xD;
      including diabetes and cardiovascular disease. Our group have previously shown that fruit&#xD;
      polyphenol extracts, when consumed immediately before a mixed carbohydrate meal, reduce&#xD;
      postprandial glycaemia. The aim of this study is to investigate the effects of a blackcurrant&#xD;
      polyphenol extract and citrus polyphenol extract (and their combination), on postprandial&#xD;
      glycaemia, insulinaemia and gastrointestinal hormone concentrations following a mixed&#xD;
      carbohydrate test meal. It is hypothesised that blackcurrant and citrus extracts alone will&#xD;
      inhibit glycaemia compared to placebo, and a combination of the two will have a greater&#xD;
      effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intake of carbohydrate-rich foods transiently increases blood glucose levels (known as&#xD;
      postprandial glycaemia). Repeated high postprandial glucose responses are evidenced to&#xD;
      dysregulate functional proteins, oxidative stress and pancreatic beta cell function; thus&#xD;
      increasing the risk of diabetes and cardiovascular disease. Accordingly, meals that elicit a&#xD;
      reduced, or more gradual, rise in blood glucose levels are desirable. Fruit polyphenols may&#xD;
      help to limit the glucose excursion following a high carbohydrate meal. Previous research by&#xD;
      our group has demonstrated that blackcurrant polyphenols significantly inhibited the average&#xD;
      incremental area under the curve (T+0 to +30 min) of plasma glucose. Possible mechanisms&#xD;
      include inhibition of intestinal enzymes and inhibition of intestinal glucose absorption by&#xD;
      decreasing Sodium-glucose linked transporter 1 (SGLT-1) / Glucose transporter 2 (GLUT-2)&#xD;
      glucose transporter activity. In vitro data suggests that citrus polyphenols may impact on&#xD;
      carbohydrate metabolism by binding to starch molecules, however, effects on postprandial&#xD;
      glycaemia are not yet known. Blackcurrants and citrus fruits have distinct polyphenol&#xD;
      profiles and may therefore act on glucose homeostasis via different mechanisms. Blackcurrants&#xD;
      are rich in anthocyanins and flavanols, whereas citrus fruits are rich in flavanones,&#xD;
      hesperetin and naringenin. Theoretically, combining blackcurrant with citrus extracts may&#xD;
      have synergistic effects.&#xD;
&#xD;
      The aim of this study is to investigate the effects of blackcurrant polyphenol extracts and&#xD;
      citrus polyphenol extracts (and their combination), on postprandial glycaemia, insulinaemia&#xD;
      and gastrointestinal hormone concentrations following a mixed carbohydrate test meal. It is&#xD;
      hypothesised that blackcurrant and citrus extracts alone will inhibit glycaemia compared to&#xD;
      placebo, a combination of the two will have a greater effect.&#xD;
&#xD;
      Study design: A randomised, controlled, double-blind, cross-over study will be conducted.&#xD;
      Subjects will consume different drinks at 4 separate study visits. Drinks will contain&#xD;
      either: blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract&#xD;
      (low dose), blackcurrant and citrus extract (low dose + low dose), or placebo (no&#xD;
      polyphenols). The study will utilise an incomplete block design. Subjects will consume the&#xD;
      placebo drink and 3 out of 4 of the polyphenol-containing drinks during the study. At least a&#xD;
      7-day wash-out period will be required between study days. Baseline (fasted) blood samples&#xD;
      will be taken in duplicate at T-10 min and T-5 min before consuming the test drink (T+0 min).&#xD;
      Immediately following consumption of the drink, a mixed carbohydrate test meal will be&#xD;
      consumed. Further blood samples will be collected at 10 min intervals for the first 30 min&#xD;
      and then every 15 min until T+90 min and at T+120 min. Blood samples will be analysed for&#xD;
      plasma glucose, insulin, glucose-dependent insulinotropic peptide (GIP), glucagon-like&#xD;
      peptide 1 (GLP-1), peptide YY (PYY), C-peptide and nonesterified fatty acids (NEFA).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2017</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">February 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Incomplete block cross-over design. Each participant receives placebo plus 3 out of 4 active treatments.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial glycaemia (iAUC 0-30 min)</measure>
    <time_frame>30 min</time_frame>
    <description>The primary endpoint is iAUC 0-30 min for plasma glucose concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial glycaemia: iAUC 0-120 min</measure>
    <time_frame>120 min</time_frame>
    <description>iAUC 0-120 min for plasma glucose concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glycaemia: iCmax</measure>
    <time_frame>120 min</time_frame>
    <description>iCmax for plasma glucose concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glycaemia: Tmax</measure>
    <time_frame>120 min</time_frame>
    <description>Tmax for plasma glucose concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glycaemia: absolute concentrations at specific time points</measure>
    <time_frame>120 min</time_frame>
    <description>Absolute concentrations at specific time points, for plasma glucose concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial insulinemia: iAUC 0-30 min</measure>
    <time_frame>30 min</time_frame>
    <description>iAUC 0-30 min for serum insulin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial insulinemia: iAUC 0-120 min</measure>
    <time_frame>120 min</time_frame>
    <description>iAUC 0-120 min for serum insulin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial insulinemia: iCmax</measure>
    <time_frame>120 min</time_frame>
    <description>iCmax, for serum insulin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial insulinemia: Tmax</measure>
    <time_frame>120 min</time_frame>
    <description>Tmax for serum insulin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial insulinemia: absolute concentrations at specific time points</measure>
    <time_frame>120 min</time_frame>
    <description>Absolute concentrations at specific time points, for serum insulin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial C-peptide: iAUC 0-30 min</measure>
    <time_frame>30 min</time_frame>
    <description>iAUC 0-30 min for plasma C-peptide concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial C-peptide: iAUC 0-120 min</measure>
    <time_frame>30 min</time_frame>
    <description>iAUC 0-120 min for plasma C-peptide concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial C-peptide: iCmax</measure>
    <time_frame>120 min</time_frame>
    <description>iCmax for plasma C-peptide concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial C-peptide: Tmax</measure>
    <time_frame>120 min</time_frame>
    <description>Tmax for plasma C-peptide concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial C-peptide: Absolute concentrations at specific time points</measure>
    <time_frame>120 min</time_frame>
    <description>Absolute concentrations at specific time points, for plasma C-peptide concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial non-esterified fatty acids (NEFA): iAUC 0-30 min</measure>
    <time_frame>30 min</time_frame>
    <description>iAUC 0-30 min for serum NEFA concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial non-esterified fatty acids (NEFA): iAUC 0-120 min</measure>
    <time_frame>120 min</time_frame>
    <description>iAUC 0-120 min for serum NEFA concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial non-esterified fatty acids (NEFA): iCmax</measure>
    <time_frame>120 min</time_frame>
    <description>iCmax for serum NEFA concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial non-esterified fatty acids (NEFA): Tmax</measure>
    <time_frame>120 min</time_frame>
    <description>Tmax for serum NEFA concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial non-esterified fatty acids (NEFA): Absolute concentrations at specific time points</measure>
    <time_frame>120 min</time_frame>
    <description>Absolute concentrations at specific time points, for serum NEFA concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood glucose-dependent insulinotropic peptide (GIP): iAUC 0-30 min</measure>
    <time_frame>30 min</time_frame>
    <description>iAUC 0-30 min for plasma GIP concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood glucose-dependent insulinotropic peptide (GIP): iAUC 0-120 min</measure>
    <time_frame>120 min</time_frame>
    <description>iAUC 0-120 min for plasma GIP concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood glucose-dependent insulinotropic peptide (GIP): iCmax</measure>
    <time_frame>120 min</time_frame>
    <description>iCmax, for plasma GIP concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood glucose-dependent insulinotropic peptide (GIP): Tmax</measure>
    <time_frame>120 min</time_frame>
    <description>Tmax for plasma GIP concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood glucose-dependent insulinotropic peptide (GIP): Absolute concentrations at specific time points</measure>
    <time_frame>120 min</time_frame>
    <description>Absolute concentrations at specific time points, for plasma GIP concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood Glucagon-like peptide 1 (GLP-1): iAUC 0-30 min</measure>
    <time_frame>30 min</time_frame>
    <description>iAUC 0-30 min for plasma GLP-1 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood Glucagon-like peptide 1 (GLP-1): iAUC 0-120 min</measure>
    <time_frame>120 min</time_frame>
    <description>iAUC 0-120 min, for plasma GLP-1 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood Glucagon-like peptide 1 (GLP-1): iCmax</measure>
    <time_frame>120 min</time_frame>
    <description>iCmax for plasma GLP-1 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood Glucagon-like peptide 1 (GLP-1): Tmax</measure>
    <time_frame>30 min</time_frame>
    <description>Tmax for plasma GLP-1 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood Glucagon-like peptide 1 (GLP-1): Absolute concentrations at specific time points</measure>
    <time_frame>120 min</time_frame>
    <description>Absolute concentrations at specific time points, for plasma GLP-1 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood peptide YY (PYY): iAUC 0-30 min</measure>
    <time_frame>30 min</time_frame>
    <description>iAUC 0-30 min for plasma PYY concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood peptide YY (PYY): iAUC 0-120 min</measure>
    <time_frame>120 min</time_frame>
    <description>iAUC 0-120 minfor plasma PYY concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood peptide YY (PYY): iCmax</measure>
    <time_frame>120 min</time_frame>
    <description>iCmax for plasma PYY concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood peptide YY (PYY): Tmax</measure>
    <time_frame>120 min</time_frame>
    <description>Tmax for plasma PYY concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial blood peptide YY (PYY): Absolute concentrations at specific time points</measure>
    <time_frame>120 min</time_frame>
    <description>Absolute concentrations at specific time points, for plasma PYY concentrations</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Food diary (estimated/unweighed)</measure>
    <time_frame>7-days, collected at screening</time_frame>
    <description>Habitual dietary intake analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>VAS measures of the palatability of the study drink</measure>
    <time_frame>10 min following the test drink</time_frame>
    <description>Descriptive statistics</description>
  </other_outcome>
  <other_outcome>
    <measure>VAS measures of mood, satiety and digestive comfort</measure>
    <time_frame>120 min</time_frame>
    <description>Descriptive statistics</description>
  </other_outcome>
  <other_outcome>
    <measure>Buccal mouth swab</measure>
    <time_frame>One off sample, collected at screening</time_frame>
    <description>Future exploratory analysis of lactase activity via the derived allele at the European lactase persistence (LP) locus</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Postprandial Period</condition>
  <arm_group>
    <arm_group_label>Treatment arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the placebo, citrus extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the placebo, blackcurrant extract (low dose), citrus extract (low dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blackcurrant extract (low dose)</intervention_name>
    <description>Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.</description>
    <arm_group_label>Treatment arm 1</arm_group_label>
    <arm_group_label>Treatment arm 3</arm_group_label>
    <arm_group_label>Treatment arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.</description>
    <arm_group_label>Treatment arm 1</arm_group_label>
    <arm_group_label>Treatment arm 2</arm_group_label>
    <arm_group_label>Treatment arm 3</arm_group_label>
    <arm_group_label>Treatment arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citrus extract (low dose)</intervention_name>
    <description>Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.</description>
    <arm_group_label>Treatment arm 1</arm_group_label>
    <arm_group_label>Treatment arm 2</arm_group_label>
    <arm_group_label>Treatment arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blackcurrant extract (high dose)</intervention_name>
    <description>Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.</description>
    <arm_group_label>Treatment arm 1</arm_group_label>
    <arm_group_label>Treatment arm 2</arm_group_label>
    <arm_group_label>Treatment arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blackcurrant and citrus extracts (low dose / low dose)</intervention_name>
    <description>Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.</description>
    <arm_group_label>Treatment arm 2</arm_group_label>
    <arm_group_label>Treatment arm 3</arm_group_label>
    <arm_group_label>Treatment arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-70 years&#xD;
&#xD;
          -  Men and women&#xD;
&#xD;
          -  Healthy (free of diagnosed diseases listed in the exclusion criteria)&#xD;
&#xD;
          -  Body Mass Index 18-35 kg/m2&#xD;
&#xD;
          -  Able to understand the information sheet and willing to comply with study protocol&#xD;
&#xD;
          -  Able to give informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those diagnosed with Phenylketonuria (PKU)&#xD;
&#xD;
          -  Those with known or suspected food intolerances, allergies or hypersensitivity&#xD;
&#xD;
          -  Women who are known to be pregnant or who are intending to become pregnant over the&#xD;
             course of the study&#xD;
&#xD;
          -  Women who are breast feeding&#xD;
&#xD;
          -  Participation in another clinical trial&#xD;
&#xD;
          -  Those who have donated blood within 3 months of the screening visit and participants&#xD;
             for whom participation in this study would result in having donated more than 1500&#xD;
             millilitres of blood in the previous 12 months.&#xD;
&#xD;
          -  Full Blood Counts and Liver Function test results outside of the normal range.&#xD;
&#xD;
          -  Current smokers, or reported giving up smoking within the last 6 months&#xD;
&#xD;
          -  History of substance abuse or alcoholism&#xD;
&#xD;
          -  Reported history of Cardiovascular disease, diabetes (or fasting glucose ≥ 7.1&#xD;
             mmol/L), cancer, kidney, liver or bowel disease, gastrointestinal disorder or use of&#xD;
             drug likely to alter gastrointestinal function&#xD;
&#xD;
          -  Unwilling to restrict consumption of specified high polyphenol foods for 48 h before&#xD;
             the study&#xD;
&#xD;
          -  Weight change &gt;3kg in preceding 2 months&#xD;
&#xD;
          -  Blood pressure ≥160/100 mmHg&#xD;
&#xD;
          -  Total cholesterol ≥ 7.5 mmol/L; fasting triacylglycerol concentrations ≥ 5.0 mmol/L&#xD;
&#xD;
          -  Medications that may interfere with the study: alpha-glucosidase inhibitors (acarbose:&#xD;
             Glucobay), insulin sensitizing drugs (metformin: Glucophage, Glucophage SR, Eucreas,&#xD;
             Janumet; thiazolidinediones: Actos, Competact), sulfonylureas (Daonil, Diamicron,&#xD;
             Diamicron MR, Glibenese, Minodiab, Amaryl Tolbutamide), and lipid lowering drugs&#xD;
             (statins, nicotinic acid, colestyramine anhydrous, ezetimibe, fibrates). Other&#xD;
             medications should be reviewed by medical representative from KCL on a case by case&#xD;
             basis.&#xD;
&#xD;
          -  Nutritional supplements that may interfere with the study: higher dose&#xD;
             vitamins/minerals (&gt;200% Recommend Nutrient Intake), B vitamins, Vitamin C, calcium,&#xD;
             copper, chromium, iodine, iron, magnesium, manganese, phosphorus, potassium and zinc.&#xD;
             Subjects already taking vitamin or minerals at a dose around 100% or less up to 200%&#xD;
             of the RNI, or evening primrose/algal/fish oil supplements will be asked to maintain&#xD;
             habitual intake patterns, ensuring that they take them every day and not sporadically.&#xD;
             They will be advised not to stop taking supplements or start taking new supplements&#xD;
             during the course of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy L Hall, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metabolic Research Unit</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Castro-Acosta ML, Smith L, Miller RJ, McCarthy DI, Farrimond JA, Hall WL. Drinks containing anthocyanin-rich blackcurrant extract decrease postprandial blood glucose, insulin and incretin concentrations. J Nutr Biochem. 2016 Dec;38:154-161. doi: 10.1016/j.jnutbio.2016.09.002. Epub 2016 Sep 14.</citation>
    <PMID>27764725</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blackcurrant</keyword>
  <keyword>Citrus</keyword>
  <keyword>Polyphenols</keyword>
  <keyword>Glucose</keyword>
  <keyword>Postprandial</keyword>
  <keyword>Metabolism</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

